• Aurora A Overexpression in High-Risk Retinoblastoma

  2026-09-11

  A 2024 study identifies Aurora kinase A overexpression as a frequent feature of retinoblastoma and links it to histopathologic factors associated with aggressive disease and poor chemotherapy response. By combining patient tissue analysis with genetic, pharmacologic, cellular, and xenograft models, the work supports AURKA as a biomarker-informed therapeutic target while highlighting the need for prospective validation.

• CK2 as a Translational Target: From Cancer to CIAV

  2026-09-10

  CX-4945 (Silmitasertib) offers a mechanistically grounded way to interrogate CK2 biology across oncology and host–virus research. This article connects CK2-dependent signaling, apoptosis, and cell-cycle control with new evidence that CIAV exploits host CK2α to stabilize VP2 and promote replication, while defining the experimental boundaries required for credible translation.

• (-)-Blebbistatin: NM II Inhibition Workflows

  2026-09-10

  Use (-)-Blebbistatin to separate non-muscle myosin II–dependent mechanics from channel-intrinsic excitability, with practical workflows spanning live-cell imaging, migration assays, and cardiac models. Its reversible, selective profile supports paired inhibition, washout, and temperature-challenge experiments rather than endpoint-only cytoskeletal measurements.

• GSTA1, Glutathione Depletion, and α-Amanitin Toxicity

  2026-09-09

  A 2026 study identifies GSTA1 as an unexpected driver of α-amanitin hepatotoxicity rather than a purely protective detoxification enzyme. Integrated animal, cellular, transcriptomic, metabolomic, docking, and DARTS evidence indicates that α-amanitin-induced GSTA1 upregulation accelerates glutathione depletion and reactive oxygen species accumulation, highlighting GSTA1 as a mechanistically relevant target in acute liver injury research.

• SCP4, H3T3 Dephosphorylation, and Chromosome Stability

  2026-09-09

  The EMBO Reports study identifies SCP4 as a mitotic histone H3T3 phosphatase that balances Haspin-dependent phosphorylation, controls chromosomal passenger complex recruitment, and supports accurate chromosome segregation. Its findings connect dysregulated SCP4 activity with chromosome lagging, aneuploidy, and early embryonic mitotic failure, while suggesting experimental frameworks for studying phosphatase-dependent genome stability.

• JHU-083 Workflows for Glutaminase Research

  2026-09-08

  JHU-083 enables mechanism-focused glutaminase pathway research in cerebral CD11b cells, experimental cerebral malaria models, and neuro-redox assays. This guide connects glutamate measurements with orthogonal oxidative-stress readouts while providing practical preparation, dosing, and troubleshooting strategies.

• Fluoxetine HCl: From Serotonin to Motivation

  2026-09-08

  A translational perspective on how Fluoxetine HCl connects serotonergic signaling, neuroplasticity, and motivation research—and how developmental SSRI findings sharpen experimental design.

• Low-Dose Orlistat Enhances Oxaliplatin in CRC

  2026-09-07

  The reference study reports that subtoxic orlistat enhanced oxaliplatin-induced cytotoxicity and apoptosis in colorectal cancer models, with activity supported by in silico synergy analysis and patient-derived xenografts. Its apoptosis-focused gene-expression analysis provides a mechanistic starting point, while the preclinical design highlights the need for further dose, toxicity, and clinical validation.

• Dutasteride Experimental Workflows for Prostate Research

  2026-09-07

  Dutasteride is a dual 5-alpha-reductase inhibitor for dissecting testosterone-to-DHT signaling, growth control, and apoptosis in prostate models. This practical guide connects concentration planning, metabolite measurements, and cell-fate assays with a cross-disciplinary framework inspired by recent hepatocyte–macrophage research.

• Dextromethorphan hydrobromide in Cell Assays

  2026-09-05

  A scenario-based guide to using Dextromethorphan hydrobromide (SKU B3478) in excitotoxicity, viability, proliferation, and cytotoxicity workflows. It explains dose interpretation, solution handling, controls, assay compatibility, and practical supplier-selection criteria without overstating preclinical evidence.

• HyperScribe T7 High Yield RNA Synthesis Kit Workflow

  2026-09-04

  Build a practical, high-yield RNA workflow for IRES reporter assays, modified transcripts, translation studies, and RNA interference experiments. This guide connects template design and RNA quality control with troubleshooting decisions that improve functional assay performance.

• CA-074 Me: Reliable Cathepsin B Inhibition

  2026-09-04

  This scenario-driven guide explains how CA-074 Me (Cathepsin B inhibitor), SKU A8239, can clarify lysosomal protease contributions in viability, apoptosis, necroptosis, and inflammation experiments. It covers selectivity, solvent handling, controls, imaging interpretation, and practical vendor-selection criteria.

• Machine Learning for Senolytic Discovery

  2026-09-03

  The reference study shows that cost-effective machine learning can identify senolytic candidates from small, heterogeneous datasets compiled from published research. Computational screening followed by human-cell validation identified ginkgetin, periplocin, and oleandrin, demonstrating a practical route for reducing early-stage drug-screening costs while preserving experimental confirmation.

• Cisapride R 51619: Designing Better Cardiotoxicity Assays

  2026-09-03

  Cisapride (R 51619) can connect 5-HT4 receptor signaling with hERG-mediated cardiac risk in integrated assays. This guide shows how to combine molecular electrophysiology, iPSC-derived cardiomyocytes, and deep-learning phenotyping without confusing mechanism with phenotype.

• 5X Protein Loading Buffer (Reducing) Guide

  2026-09-02

  5X Protein Loading Buffer (Reducing) supports reproducible protein sample preparation for conventional SDS-PAGE by combining SDS, a sulfhydryl reducing agent, tracking dye, and buffer salts in a concentrated formulation. It is intended for denaturing, reducing workflows and should not be used when native protein conformation or non-reducing conditions must be preserved.

7951 records 1/531 page Next 12345 下5页 Last page